Crizanlizumab

Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1) . Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease[1][2][3].

Product Specifications

CAS Number

[1690318-25-2]

Product Name Alternative

HSel001; SEG101

UNSPSC

12352203

Target

P-selectin

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/crizanlizumab.html

Purity

95.0

Solubility

H2O

Smiles

[Crizanlizumab]

Molecular Weight

(146.21 kDa)

References & Citations

[1]Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020) . |[2]Ataga KI, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376 (5) :429-439. |[3]Ravirajsinh Jadeja, et al. Therapeutic potential of Crizanlizumab (anti-P-selectin) in improving sickle cell retinopathy in mice. Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4747.